Literature DB >> 11942375

Differentiation of radiation necrosis from tumor progression using proton magnetic resonance spectroscopy.

H P Schlemmer1, P Bachert, M Henze, R Buslei, K K Herfarth, J Debus, G van Kaick.   

Abstract

We report on a young woman who was treated by stereotactic radiotherapy for recurrence of an initially resected low-grade astrocytoma. MRI follow-up examination 7 months after radiotherapy showed a gadolinium-DTPA-enhancing mass lesion indicative of high-grade tumor progression. This assumption was also supported by positron emission tomography with [2-18F]fluoro-2-deoxy-D-glucose (FDG-PET). In contrast, proton MR spectroscopy (1H-MRS) indicated radiation necrosis, which was confirmed histopathologically in surgical specimens. Subsequent follow-up examinations up to 19 months after surgery showed no evidence of tumor recurrence.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11942375     DOI： 10.1007/s002340100703

Source DB:  PubMed          Journal:  Neuroradiology        ISSN： 0028-3940            Impact factor:   2.804


  32 in total

Review 1.  Treatment induced necrosis versus recurrent/progressing brain tumor: going beyond the boundaries of conventional morphologic imaging.

Authors:  Rajan Jain; Jayant Narang; Pia M Sundgren; David Hearshen; Sona Saksena; Jack P Rock; Jorge Gutierrez; Tom Mikkelsen
Journal:  J Neurooncol       Date:  2010-02-24       Impact factor: 4.130

2.  Radiation necrosis versus glioma recurrence: conventional MR imaging clues to diagnosis.

Authors:  Mark E Mullins; Glenn D Barest; Pamela W Schaefer; Fred H Hochberg; R Gilberto Gonzalez; Michael H Lev
Journal:  AJNR Am J Neuroradiol       Date:  2005-09       Impact factor: 3.825

Review 3.  Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: pitfalls in neurooncology.

Authors:  Alba A Brandes; Alicia Tosoni; Federica Spagnolli; Giampiero Frezza; Marco Leonardi; Fabio Calbucci; Enrico Franceschi
Journal:  Neuro Oncol       Date:  2008-04-09       Impact factor: 12.300

Review 4.  New advances that enable identification of glioblastoma recurrence.

Authors:  Isaac Yang; Manish K Aghi
Journal:  Nat Rev Clin Oncol       Date:  2009-10-06       Impact factor: 66.675

5.  Diagnostic dilemma of pseudoprogression in the treatment of newly diagnosed glioblastomas: the role of assessing relative cerebral blood flow volume and oxygen-6-methylguanine-DNA methyltransferase promoter methylation status.

Authors:  D-S Kong; S T Kim; E-H Kim; D H Lim; W S Kim; Y-L Suh; J-I Lee; K Park; J H Kim; D-H Nam
Journal:  AJNR Am J Neuroradiol       Date:  2011-01-20       Impact factor: 3.825

6.  Brain irradiation: effects on normal brain parenchyma and radiation injury.

Authors:  Pia C Sundgren; Yue Cao
Journal:  Neuroimaging Clin N Am       Date:  2009-11       Impact factor: 2.264

7.  Automated brain tumor segmentation using spatial accuracy-weighted hidden Markov Random Field.

Authors:  Jingxin Nie; Zhong Xue; Tianming Liu; Geoffrey S Young; Kian Setayesh; Lei Guo; Stephen T C Wong
Journal:  Comput Med Imaging Graph       Date:  2009-05-14       Impact factor: 4.790

8.  Diffusion-weighted imaging in the follow-up of treated high-grade gliomas: tumor recurrence versus radiation injury.

Authors:  Patrick A Hein; Clifford J Eskey; Jeffrey F Dunn; Eugen B Hug
Journal:  AJNR Am J Neuroradiol       Date:  2004-02       Impact factor: 3.825

9.  MR spectroscopy in the evaluation of recurrent contrast-enhancing lesions in the posterior fossa after tumor treatment.

Authors:  P Weybright; P Maly; D Gomez-Hassan; C Blaesing; P C Sundgren
Journal:  Neuroradiology       Date:  2004-04-23       Impact factor: 2.804

10.  Radiological progression of cerebral metastases after radiosurgery: assessment of perfusion MRI for differentiating between necrosis and recurrence.

Authors:  Friso W A Hoefnagels; Frank J Lagerwaard; Esther Sanchez; Cornelis J A Haasbeek; Dirk L Knol; Ben J Slotman; W Peter Vandertop
Journal:  J Neurol       Date:  2009-03-10       Impact factor: 4.849
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.